Phenobarbital for Neonatal Seizures: Response Rate and Predictors of Refractoriness

摘要

Background Phenobarbital is the first-line choice for neonatal seizures treatment, despite a response rate of approximately 45%. Failure to respond to acute anticonvulsants is associated with poor neurodevelopmental outcome, but knowledge on predictors of refractoriness is limited.